Reality Check

MMIT Reality Check on Multiple Myeloma (Oct 2021)

Payer Coverage: A review of market access for multiple myeloma treatments shows that under the pharmacy benefit, about half of the lives under commercial formularies are covered with utilization management restrict...
0 Comments

MMIT Reality Check on Sickle Cell Disease (Sept 2021)

Payer Coverage: A review of market access for sickle cell disease treatments shows that under the pharmacy benefit, about 38% of the lives under commercial formularies are covered with utilization management restri...
0 Comments

MMIT Reality Check on Schizophrenia (Sept 2021)

Payer Coverage: A review of market access for schizophrenia treatments shows that under the pharmacy benefit, about 26% of the lives under commercial formularies are covered with utilization management restrictions...
0 Comments

MMIT Reality Check on Acute Migraine (Sept 2021)

Payer Coverage: A review of market access for acute migraine treatments shows that under the pharmacy benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictio...
0 Comments

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2021)

According to our recent payer coverage analysis for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer treatments, combined with news from key healthcare influence...
0 Comments

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2021)

According to our recent payer coverage analysis for non-small cell lung cancer systemic therapy treatments treatments, combined with news from key healthcare influencers, market access is shifting in this drug lands...
0 Comments

MMIT Reality Check on Ulcerative Colitis (Aug 2021)

According to our recent payer coverage analysis for ulcerative colitis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this ...
0 Comments

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2021)

According to our recent payer coverage analysis for Duchenne muscular dystrophy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense...
0 Comments

MMIT Reality Check on Parkinson’s Disease (Aug 2021)

According to our recent payer coverage analysis for Parkinson’s disease treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of th...
0 Comments

MMIT Reality Check on Kidney Cancer (July 2021)

According to our recent payer coverage analysis for kidney cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. To help make sense of this new r...
0 Comments